Adipotide Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 28 days (4 weeks) standard; up to 8 weeks with a cautious titration approach, followed by a mandatory minimum 4-week washout
• Frequency: Once daily, consistent timing preferred
• Common delivery routes: Subcutaneous injection only
• Key timing notes: Morning administration is commonly preferred; daily consistency in timing matters more than the exact clock time

Who This Protocol Is For

Adipotide attracts researchers and self-experimenters with one specific goal: targeted fat loss through a mechanism unlike anything else in the peptide space. It does not suppress appetite, alter metabolism through hormonal signaling, or inhibit fat absorption. It works by destroying the blood vessels that supply white adipose tissue, triggering programmed cell death in fat cells directly. That mechanism is the reason it draws interest, and it is also the reason this protocol demands more careful attention to safety monitoring than most.

People who investigate an Adipotide protocol are almost universally motivated by body composition, specifically the reduction of white adipose tissue when other approaches have plateaued. This is not a general wellness or longevity compound. It is not run for joint recovery, cognitive support, or systemic health goals. The intended effect is narrowly defined: fat cell reduction by vascular ablation.

Experience level matters significantly here. Because the gap between an effective dose and a dose that stresses kidney function is narrow, this is a compound that experienced researchers treat with considerable care. Those without prior subcutaneous injection experience and a clear plan for kidney function monitoring are not well-positioned to run this protocol. Safety monitoring is not optional; it is structural to how any Adipotide cycle is run.

Delivery route is fixed. All published study designs, including the primate research and the Phase 1 human trial, used subcutaneous injection only. There is no oral, nasal, or sublingual Adipotide protocol in the literature.

How Is an Adipotide Cycle Structured?

An Adipotide cycle has a simple shape: a fixed daily injection period followed by a mandatory recovery break. The standard approach is 28 days of once-daily subcutaneous injections, then a washout period of at least four weeks before considering another cycle. Think of it as a sprint rather than a sustained effort: the compound runs at a steady dose for a defined window, the body responds during and shortly after that window, and then the cycle ends completely.

The 28-day structure comes from the primate research and from the design of the discontinued Phase 1 human trial, both of which used this framework. An alternative approach extends the cycle to eight weeks using a gradual titration pattern, where the dose starts lower and steps upward incrementally across weeks rather than holding flat throughout. This titration approach is favored by researchers who want an early warning system for adverse kidney response before the full dose level is reached.

A noteworthy feature of Adipotide's mechanism is that fat loss has been observed to continue for roughly two to three weeks after the cycle ends, a post-treatment carry-over effect seen in the primate studies. The 28-day on-cycle is not the complete window of effect. No published data supports running Adipotide beyond eight weeks or running consecutive cycles without a full washout period in between.

How Your Dose Is Determined

What moves an Adipotide dose:

• Your goal: Adipotide is run for one goal type: reduction of white adipose tissue. Within that goal, body weight is a meaningful input to where the dose lands. Someone at a lower body weight reaches a different absolute dose than someone significantly heavier, even when both are pursuing the same objective.
• Experience level: Researchers newer to Adipotide almost universally start at the conservative lower boundary of the range and hold there for the full cycle, observing the response before considering any adjustment. More experienced researchers who have established a baseline understanding of their individual tolerance may approach the upper portion of the conservative range, but only with active kidney monitoring in place.
• Delivery route: Subcutaneous injection is the only route with any research behind it, so there is no route-driven dose adjustment. All dose references assume subcutaneous administration.
• Individual response and kidney function: More than almost any other research peptide, Adipotide requires continuous attention to individual response. Kidney function markers can begin to shift within the first week of dosing. Two people at the same body weight pursuing the same goal can have meaningfully different kidney response profiles, which means no fixed dose fits everyone even when all other variables are identical.

The narrow therapeutic window is the defining feature of Adipotide dosing. The range that produces meaningful fat loss sits closer to the range that stresses kidney function than most researchers would prefer. That proximity is why conservative dosing is strongly emphasized across all research community protocols, and why active monitoring is a structural part of the cycle rather than an afterthought. There is no single dose that works for everyone, which is precisely what the app accounts for when building a personalized protocol.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your body weight, your fat-loss goal, and your kidney function baseline and builds your Adipotide protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Adipotide?

Adipotide is administered once daily. That frequency reflects both the structure of all study protocols and the compound's mechanism: a consistent daily presence is needed to maintain the vascular-targeting effect throughout the cycle window.

Timing within the day is less rigidly specified than frequency itself, but morning administration is the most commonly preferred approach. What matters more than the exact clock time is consistency from day to day. Taking the injection at a stable time each day keeps the protocol disciplined and reduces one variable in a compound where controlling variables is genuinely important.

Because subcutaneous injection is the only route, daily injection site rotation is a required part of the frequency plan. Rotating between the abdomen, thigh, and upper arm on a daily basis prevents tissue irritation and maintains absorption quality across the cycle.

Loading and Maintenance Phases

Adipotide does not use a loading phase, and that absence is meaningful. With many peptides, a loading phase delivers a higher initial dose to establish elevated tissue levels quickly before settling into a lower maintenance dose. Adipotide works the opposite way: any upfront dose spike increases the immediate kidney toxicity risk without a demonstrated efficacy benefit. Starting at the full therapeutic dose from day one, or stepping upward gradually in the titration approach, is the standard norm. Attempting a loading dose is explicitly identified as a protocol error.

The standard 28-day protocol holds the dose consistent from day one through the end of the cycle. There is no separate maintenance phase because the entire cycle functions as a fixed therapeutic window rather than a two-phase structure.

The 8-week titration approach introduces a different structure: the dose steps upward across week-pairs as a deliberate risk-mitigation strategy. This is not a loading-and-maintenance distinction; it is a gradual escalation designed to give kidney monitoring a chance to catch any early adverse signal before the full dose tier is reached. Once the target level is established, it holds through the remainder of the cycle.

Both approaches end the same way: a complete stop followed by a mandatory washout before any subsequent cycle is considered.

Off-Cycle Considerations

The off-cycle period after an Adipotide cycle is not optional. It is built into the protocol design because the primary safety concern, kidney function stress, requires time to fully resolve before the compound is introduced again.

The primate research provides the clearest reference point for washout duration: kidney function markers in treated animals returned to baseline within approximately 28 days following the end of treatment. That finding establishes a biologically grounded minimum of at least four weeks off before considering another cycle. Some researchers extend the washout to six weeks or longer, particularly if any kidney function elevation appeared during the prior cycle.

The post-treatment carry-over effect is worth keeping in mind when planning the off-cycle window. Fat loss has been observed to continue for roughly two to three weeks after the cycle ends, based on the primate data. The washout period is not entirely inactive: the body continues responding to the vascular changes initiated during the cycle.

No published data supports running consecutive Adipotide cycles without a washout, and no data characterizes what happens to kidney function under chronic dosing. The mandatory washout is where the evidence unambiguously lands, and it should be treated as a hard stop rather than a suggestion.

What to Expect Week by Week

• Week 1 to 2: The most commonly reported early experiences are injection site reactions, mild burning or itching for a few minutes post-injection, and the first signs that the compound is active. Some users report early weight changes, though initial shifts often reflect fluid rather than confirmed fat tissue reduction. Kidney function monitoring is most critical in this window; primate data showed kidney marker changes can appear after the first week of treatment.
• Week 3 to 4: The standard 28-day protocol reaches its end here. Primate studies recorded the most pronounced fat loss effects across this period. For the standard protocol, the cycle concludes at week four and the washout begins immediately. Community reports describe this as the window when measurable body composition changes become more apparent, though individual variation is significant.
• Week 5 to 8 (titration protocol only): Researchers running the gradual 8-week approach are in the upper dose tiers by this point. Efficacy may begin to plateau toward the end of this window, and some sources note diminishing returns beyond six weeks. Active kidney monitoring continues throughout.
• Post-cycle carry-over: One of Adipotide's more distinctive characteristics is continued fat loss after the cycle ends. In the primate study, this carry-over persisted for approximately three weeks post-treatment, consistent with community reports describing continued weight loss in the weeks following a 28-day course.

For a well-run standard protocol, a researcher who maintains consistent daily injection timing, rotates injection sites properly, stays well-hydrated, and monitors kidney function throughout the cycle commonly reports a meaningful shift in body composition by the end of the cycle, with the effect extending into the washout window. The primate study observed substantial fat loss in treated animals over the observation period, and community accounts have described comparable trajectories over shorter windows. These are commonly reported patterns drawn from animal research and anecdotal protocol data, not guarantees. Individual results vary based on dose, consistency, starting body composition, and kidney function response.

Common Protocol Mistakes

Assuming the primate dose scales to humans. The dose used in the key primate study was substantially higher than what conservative human protocols use, and the two figures do not scale directly. Applying primate-level dosing in a human context risks acute renal toxicity. The conservative ceiling from research community guidance and the Phase 1 trial design sits well below the primate optimal dose.

Using a loading dose. Some researchers familiar with loading structures from other peptides attempt to front-load Adipotide. This is explicitly wrong for this compound. Spiking the dose at the start of the cycle does not improve the fat-loss outcome and sharply increases immediate kidney toxicity risk. The dose begins at the standard therapeutic level from day one.

Skipping or delaying kidney function monitoring. Kidney marker elevation can appear within the first week of a cycle. Researchers who do not establish baseline creatinine and BUN values before starting, and then monitor weekly throughout, are missing the most critical safety signal in the protocol. Any elevation requires immediate dose adjustment or discontinuation, and catching it early is only possible with active monitoring in place.

Running past 28 days without a washout. Extending a cycle without a mandatory washout allows kidney stress to accumulate. The 28-day cycle followed by a minimum four-week washout is the standard structure. Going past that boundary is not supported by any evidence and carries meaningful cumulative toxicity risk.

Inconsistent injection timing and poor site management. Taking the injection at variable times each day introduces unnecessary variability. Injecting the same site repeatedly causes tissue irritation and impairs absorption. Consistent daily timing and rotation between the abdomen, thigh, and upper arm are both standard parts of the protocol. A fine-gauge needle appropriate for subcutaneous injection is standard practice; larger gauges add unnecessary tissue trauma.

Poor storage and handling. Improper storage or vigorous shaking during reconstitution can degrade the compound before the cycle even begins. Proper storage and reconstitution practices protect compound integrity and are worth confirming before starting.

Sourcing from unverifiable suppliers. Adipotide exists only as a research chemical with no pharmaceutical-grade regulated human product available. Quality and purity are entirely dependent on the supplier. Sourcing from vendors who cannot provide third-party testing degrades the compound itself as a variable.

Regulatory Status

Adipotide is not FDA-approved for any human use and has no approved indication in any regulatory jurisdiction. It is also classified under WADA Prohibited List Category S0, meaning competitive athletes subject to anti-doping regulations are prohibited from using it both in and out of competition.

Frequently Asked Questions

How long is a typical Adipotide cycle?

The standard Adipotide cycle is 28 days of once-daily subcutaneous injections, followed by a mandatory minimum four-week washout. A cautious titration approach extends the cycle to eight weeks, stepping the dose upward gradually across week-pairs. No published data supports running beyond eight weeks.

How often do you take Adipotide?

Adipotide is taken once daily, with consistent timing each day. Morning administration is the most commonly preferred approach, though daily consistency matters more than the specific clock time. All study protocols, including the primate research and the Phase 1 human trial design, used once-daily subcutaneous injection.

Does Adipotide need a loading phase?

No. Adipotide does not use a loading phase, and attempting one is considered a protocol error. Front-loading above the standard therapeutic dose increases the immediate kidney toxicity risk without a demonstrated efficacy benefit. The dose begins at the standard therapeutic level from day one.

Do you need to cycle off Adipotide?

Yes, and the washout is mandatory. A minimum four-week off-cycle break follows each 28-day cycle, grounded in the primate data showing kidney function markers normalize within approximately 28 days post-treatment. Some researchers extend the washout to six weeks or longer. No evidence supports consecutive cycles without a full washout.

Why is kidney monitoring part of the Adipotide protocol?

Kidney function stress is the primary adverse effect observed in both rodent and primate research. The gap between an effective dose and a dose that elevates kidney markers is narrow, and those elevations can appear within the first week of dosing. Monitoring serum creatinine and BUN at baseline and then weekly throughout the cycle gives the earliest possible signal for any adverse response. This allows dose adjustment or discontinuation before stress accumulates, which is why monitoring is structural to the protocol rather than optional.

Does fat loss continue after stopping Adipotide?

In the primate research, fat loss persisted for approximately three weeks after the end of treatment, a post-treatment carry-over attributed to the continued die-off of fat cells whose blood supply was eliminated during the cycle. Community reports have described a similar pattern. This carry-over is one of Adipotide's more distinctive characteristics, and it means the washout window is not entirely inactive.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for Adipotide in one place.